Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients - MOOD-HF

Julius Maximilians Universität Würzburg0 sitesMarch 27, 2008

Overview

No summary available.

Registry

who.int

Start Date

March 27, 2008

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Julius Maximilians Universität Würzburg

•Patients must meet ALL of the following criteria:
•Age \>\= 18 years
•Chronic systolic heart failure of any etiology with
•\- current NYHA class II\-IV and
•\- at least one measurement of LVEF \< 45% by echocardiography or laevocardio\-graphy or cardio\-MRT within the preceding three months
•Diagnostic and Statistical Manual of Mental Disorders\-IV diagnosis of current major DEP based on the Structured Clinical Interview for DSM\-IV (SCID48\).
•Provision of written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•Recent history of acute myocardial infarction (\<3 months)
•Acute cardiac decompensation
•Recent (\< 3 months) or planned major cardiac surgery (\<12 months)
•Advanced renal failure (MDRD \< 30ml/min)
•Moderate or severe hepatic insufficiency (plasma levels of serum transaminases \>threefold of the upper level of the normal range) or manifest hepatic failure
•Thyreotoxicosis
•Other medical contraindication against treatment with SSRI
•Significantly reduced life expectancy due to other comorbidity (e.g. malignancy)
•Use of any antidepressants including SSRI, lithium or anti\-convulsants for mood disorder in adequate dosage, with sufficiently long duration of antidepressive treatment and clinical outcome
•Currently undergoing any form of psychotherapy